Neuroblastoma cells harbor a pattern of chromosomal aberrations that include chromosomes 1p and 11q deletions and 2p and 17q gains, as well as MYCN gene amplification with MYC overexpression. Recent research has identified RuvB-like 1 (RUVBL1) and RUVBL2 to be key mediators of the therapeutic response to a promising strategy such as serine/threonine-protein kinase ATR inhibition.